

Lucila Garcia-Contreras

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/768537/publications.pdf>

Version: 2024-02-01

25
papers

926
citations

686830

13
h-index

610482

24
g-index

27
all docs

27
docs citations

27
times ranked

1085
citing authors

#	ARTICLE	IF	CITATIONS
1	Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery. <i>Pharmaceutical Research</i> , 2009, 26, 1847-1855.	1.7	217
2	In vivo animal models for drug delivery across the lung mucosal barrier. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 1133-1151.	6.6	132
3	Inhalation drug delivery devices: technology update. <i>Medical Devices: Evidence and Research</i> , 2015, 8, 131.	0.4	111
4	Preparation and in Vivo Evaluation of a Dry Powder for Inhalation of Capreomycin. <i>Pharmaceutical Research</i> , 2008, 25, 805-811.	1.7	89
5	Dry Powder Nitroimidazopyran Antibiotic PA-824 Aerosol for Inhalation. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1338-1343.	1.4	66
6	Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1491-1504.	6.6	49
7	Mechanisms of absorption and elimination of drugs administered by inhalation. <i>Therapeutic Delivery</i> , 2013, 4, 1027-1045.	1.2	45
8	Aerosol Treatment of Cystic Fibrosis. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2003, 20, 317-356.	1.2	29
9	Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs. <i>International Journal of Pharmaceutics</i> , 2018, 549, 306-316.	2.6	23
10	Liquid-Spray or Dry-Powder Systems for Inhaled Delivery of Peptide and Proteins?. <i>American Journal of Drug Delivery</i> , 2005, 3, 29-45.	0.6	22
11	Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 331-337.	1.6	21
12	Biodegradable Cisplatin Microspheres for Direct Brain Injection: Preparation and Characterization. <i>Pharmaceutical Development and Technology</i> , 1997, 2, 53-65.	1.1	20
13	Immediate and short-term cellular and biochemical responses to pulmonary single-dose studies of insulin and H-MAP. <i>Pharmaceutical Research</i> , 2001, 18, 1685-1693.	1.7	20
14	Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 638-646.	1.6	14
15	SHetA2 Dry Powder Aerosols for Tuberculosis: Formulation, Design, and Optimization Using Quality by Design. <i>Molecular Pharmaceutics</i> , 2018, 15, 300-313.	2.3	11
16	Cryogenic Fabrication of Dry Powders to Enhance the Solubility of a Promising Anticancer Drug, SHetA2, for Oral Administration. <i>AAPS PharmSciTech</i> , 2019, 20, 20.	1.5	8
17	Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. <i>Investigational New Drugs</i> , 2018, 36, 561-570.	1.2	7
18	Inhaled Formulation Design for the Treatment of Lung Infections. <i>Current Pharmaceutical Design</i> , 2015, 21, 3875-3901.	0.9	7

#	ARTICLE	IF	CITATIONS
19	Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 130, 272-280.	2.0	6
20	Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. <i>AAPS Journal</i> , 2020, 22, 51.	2.2	5
21	Efficacy of Combined Rifampicin Formulations Delivered by the Pulmonary Route to Treat Tuberculosis in the Guinea Pig Model. <i>Pharmaceutics</i> , 2021, 13, 1309.	2.0	4
22	Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 3179-3186.	1.6	3
23	Development and validation of a reverse phase HPLC method for SHetA2, a novel anti-cancer drug, in mouse biological samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 170, 124-131.	1.4	3
24	Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2000-2008.	1.6	2
25	Abstract PO040: Chemoprevention and regression of estrogen-induced atypical endometrial hyperplasia by oral SHetA2 in a rat model. , 2021, , .		0